Waters (WAT)

Executive Summary

Waters Corporation is a global leader in analytical laboratory instruments, specializing in high-performance liquid chromatography (HPLC), mass spectrometry (MS), and thermal analysis systems. Founded in 1958 and headquartered in Milford, Massachusetts, the company serves critical markets including pharmaceuticals, life sciences, materials science, food safety, environmental testing, and clinical diagnostics. Waters’ technologies are essential for identifying and quantifying chemical and biological compounds, making them a key partner for R&D, quality control, and regulatory compliance. The company operates with a strong business model, generating recurring revenue from consumables, service, and software. With a market capitalization of approximately $30.7 billion, Waters is a mature, profitable company known for its innovation and high-margin products. Looking ahead, Waters is poised to benefit from several growth drivers. The increasing demand for biopharmaceutical analysis, particularly for monoclonal antibodies and gene therapies, is driving upgrades to next-generation LC-MS systems. The company is also expanding its presence in clinical diagnostics with new CE-marked in vitro diagnostic (IVD) kits. Additionally, Waters’ investments in digital and cloud-based informatics solutions are expected to enhance customer workflow efficiency and lock-in recurring revenue. While competition from Agilent and Thermo Fisher is intense, Waters’ reputation for precision and reliability supports its premium positioning. The company’s steady financial performance and strategic focus on high-growth end markets yield a conviction score of 75.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation LC-MS system for biopharma80% success
• Q4 2026FDA clearance for new clinical diagnostic assay70% success
• Q3 2026Q3 2026 earnings beat driven by consumables growth65% success